Skip Navigation LinksHome > March 2013 - Volume 113 - Issue 3 > New Drug Treats Rheumatoid Arthritis
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000427871.05603.e4
Drug Watch

New Drug Treats Rheumatoid Arthritis

Aschenbrenner, Diane S. MS, RN

Collapse Box


* Tofacitinib (Xeljanz) has been approved to treat moderate-to-severe rheumatoid arthritis in adults who've had an inadequate response to or cannot tolerate methotrexate.

* The drug can produce serious, even life-threatening, infections. The most common serious infections reported include pneumonia, cellulitis, herpes zoster, and urinary tract infection. Tuberculosis and other opportunistic infections are also possible.

* Tofacitinib can decrease various cell counts, and blood counts need to be assessed carefully before and during therapy.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics